Compound ID | 1738
Synonym(s): AerumabTM | Panobacumab
Class: Antibody (monoclonal antibody [mAb])
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against P. aeruginosa |
| Institute where first reported: | Aimmune Therapeutics |
| Year first mentioned: | 2020 |
| Highest developmental phase: | Phase 3 |
| External links: | |
| Guide to Pharmacology: | panobacumab |
| Citation: | https://www.nature.com/articles/s41429-020-0344-z |